| Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine (NCT05460377) | Centers for Disease Control and Prevention | 2022-07-26 |
| A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants (NCT05432141) | Sinovac Biotech Co., Ltd | 2022-06-13 |
| Physical Activity in People With Sequelae of Poliomyelitis (NCT05303545) | Institut de Sante Parasport Connecte Synergies | 2022-05-01 |
| Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT (NCT05327426) | University of Vermont | 2022-04-01 |
| Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine (NCT05163561) | Serum Institute of India Pvt. Ltd. | 2022-01-09 |
| Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants (NCT05033561) | Fidec Corporation | 2021-12-16 |
| An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses (NCT04989231) | Sinovac Biotech Co., Ltd | 2021-09-09 |
| Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines (NCT04529538) | PATH | 2021-03-26 |
| Immunogenicity nOPV2 With and Without bOPV (NCT04579510) | Centers for Disease Control and Prevention | 2021-02-08 |
| Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine (NCT05166031) | Fidec Corporation | 2020-12-01 |
| Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®) (NCT04448132) | AJ Vaccines A/S | 2020-11-20 |
| Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants (NCT05386810) | Sinovac Biotech Co., Ltd | 2020-11-05 |
| A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China (NCT04614597) | Centers for Disease Control and Prevention, China | 2020-10-29 |
| Clinical Trial of Novel OPV2 Vaccine (NCT04693286) | International Centre for Diarrhoeal Disease Research, Bangladesh | 2020-09-21 |
| Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine (NCT04386707) | Sinovac Biotech Co., Ltd | 2020-05-11 |
| Effect of Ankle-foot Orthoses on Balance Confidence (NCT04080687) | University Rehabilitation Institute, Republic of Slovenia | 2020-02-06 |
| To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years (NCT04618640) | Boryung Biopharma Co., Ltd. | 2019-12-26 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants (NCT04073459) | LG Chem | 2019-11-01 |
| Immunogenicity of Intramuscular and Intradermal IPV (NCT04063150) | Centers for Disease Control and Prevention | 2019-10-06 |
| Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization (NCT04618783) | Sinovac Biotech Co., Ltd | 2019-07-20 |
| Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study (NCT03722004) | Centers for Disease Control and Prevention | 2018-12-18 |
| A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine (NCT03554798) | Fidec Corporation | 2018-12-04 |
| A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates (NCT04544787) | Pierre Van Damme | 2018-10-22 |
| Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh (NCT03890497) | International Centre for Diarrhoeal Disease Research, Bangladesh | 2018-09-27 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants (NCT03822767) | Sinovac Biotech Co., Ltd | 2018-06-12 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants (NCT03822754) | Sinovac Biotech Co., Ltd | 2018-06-06 |
| A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. (NCT03597919) | Centers for Disease Control and Prevention, China | 2018-05-28 |
| Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China (NCT03546634) | Centers for Disease Control and Prevention, China | 2018-05-24 |
| Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months (NCT03671616) | Statens Serum Institut | 2018-05-15 |
| Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain (NCT04224519) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2018-04-15 |
| Inactivated Poliomyelitis Vaccine Made From Sabin Strain (NCT04220515) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2018-02-08 |
| Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine (NCT03821441) | Chinese Academy of Medical Sciences | 2018-01-04 |
| Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants (NCT03128489) | GlaxoSmithKline | 2017-12-01 |
| Duration of IPV Priming and Antibody Decay (NCT03202719) | Centers for Disease Control and Prevention | 2017-11-05 |
| A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV (NCT03239496) | Fidec Corporation | 2017-10-23 |
| An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants (NCT03526978) | Sinovac Biotech Co., Ltd | 2017-08-08 |
| Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan (NCT03286803) | Aga Khan University | 2017-08-01 |
| A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults (NCT03208101) | LG Chem | 2017-07-03 |
| A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine (NCT03016949) | Fidec Corporation | 2017-07-01 |
| IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults (NCT03092791) | Takeda | 2017-06-07 |
| A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants (NCT03169725) | LG Chem | 2017-05-31 |
| A Campaign-based ID fIPV Administration Trial (NCT02967783) | Medical Research Council Unit, The Gambia | 2017-02-07 |
| Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months (NCT03032419) | Statens Serum Institut | 2017-02-06 |
| Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (NCT02985320) | Sinovac Biotech Co., Ltd | 2016-10-01 |
| Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (NCT02853929) | GlaxoSmithKline | 2016-09-19 |
| Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study (NCT02847026) | Centers for Disease Control and Prevention | 2016-09-01 |
| Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (NCT02422264) | GlaxoSmithKline | 2016-01-22 |
| Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine (NCT02643368) | Centers for Disease Control and Prevention | 2015-12-01 |
| A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania (NCT02582255) | Fidec Corporation | 2015-11-01 |
| A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age (NCT02580201) | Fidec Corporation | 2015-11-01 |
| Safety and Immunogenicity of IPOVAC in Young Children (NCT02775942) | National Institute of Hygiene and Epidemiology, Vietnam | 2015-11-01 |
| Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (NCT03614702) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2015-09-15 |
| Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine (NCT02643446) | Centers for Disease Control and Prevention, China | 2015-08-01 |
| Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine (NCT02434770) | PATH | 2015-08-01 |
| Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth (NCT02428491) | Sanofi Pasteur, a Sanofi Company | 2015-04-20 |
| Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules (NCT02412514) | Centers for Disease Control and Prevention | 2015-04-01 |
| Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine (NCT02785705) | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control | 2015-04-01 |
| Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS (NCT02458183) | Boryung Pharmaceutical Co., Ltd | 2015-02-02 |
| 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants (NCT02347423) | Statens Serum Institut | 2015-02-01 |
| DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants (NCT02274285) | Sanofi Pasteur, a Sanofi Company | 2014-10-01 |
| Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine (NCT02291263) | Centers for Disease Control and Prevention | 2014-10-01 |
| Polio End-game Strategies - Poliovirus Type 2 Challenge Study (NCT02189811) | Aga Khan University | 2014-09-01 |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants (NCT02096263) | GlaxoSmithKline | 2014-04-16 |
| DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (NCT02094833) | Sanofi Pasteur, a Sanofi Company | 2014-03-01 |
| Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis (NCT02089880) | Shirley Ryan AbilityLab | 2014-02-01 |
| Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan (NCT02005536) | Sanofi Pasteur, a Sanofi Company | 2013-12-01 |
| Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults (NCT01997632) | University Hospital, Ghent | 2013-11-01 |
| Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (NCT01983540) | Sanofi Pasteur, a Sanofi Company | 2013-10-01 |
| IPV Clinical Trial - The Gambia (NCT01847872) | London School of Hygiene and Tropical Medicine | 2013-07-01 |
| Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns (NCT01870206) | Laboratorios de Biologicos y Reactivos de México, S.A. de C.V. | 2013-06-01 |
| Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (NCT01831050) | Fidec Corporation | 2013-05-01 |
| Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer (NCT01751503) | Iva Hauptmannova | 2013-03-01 |
| Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (NCT01577732) | GlaxoSmithKline | 2012-12-08 |
| Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea (NCT01568060) | GlaxoSmithKline | 2012-05-21 |
| Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine (NCT01353703) | GlaxoSmithKline | 2012-04-16 |
| Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE) (NCT01571505) | International Vaccine Institute | 2012-03-01 |
| Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE (NCT01546909) | Sanofi Pasteur, a Sanofi Company | 2012-02-01 |
| The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV) (NCT01510366) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2012-01-01 |
| Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine (NCT01475539) | Sanofi Pasteur, a Sanofi Company | 2011-11-01 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (NCT01453998) | GlaxoSmithKline | 2011-10-14 |
| Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants (NCT01444781) | Sanofi Pasteur, a Sanofi Company | 2011-09-01 |
| Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults (NCT01708720) | Pauline Verdijk | 2011-08-01 |
| Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan (NCT01389687) | Sanofi Pasteur, a Sanofi Company | 2011-07-01 |
| Regulatory Post-Marketing Surveillance Study for TETRAXIM™ (NCT01437423) | Sanofi Pasteur, a Sanofi Company | 2011-06-01 |
| Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ (NCT01358825) | GlaxoSmithKline | 2011-05-30 |
| Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers (NCT01323647) | GlaxoSmithKline | 2011-04-25 |
| Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults (NCT01323959) | GlaxoSmithKline | 2011-04-01 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine (NCT01309646) | GlaxoSmithKline | 2011-03-04 |
| The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell) (NCT02231632) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2011-01-01 |
| Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older (NCT01287949) | Sanofi Pasteur, a Sanofi Company | 2011-01-01 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (NCT01248884) | GlaxoSmithKline | 2010-12-09 |
| Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia (NCT01094171) | GlaxoSmithKline | 2010-12-03 |
| A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China (NCT01278433) | Sanofi Pasteur, a Sanofi Company | 2010-12-01 |
| A Study of the Safety of IMOVAX Polio™ in China (NCT01244464) | Sanofi | 2010-11-01 |
| Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. (NCT01214889) | Sanofi | 2010-09-01 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (NCT01171989) | GlaxoSmithKline | 2010-08-18 |
| A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants (NCT01177722) | Sanofi Pasteur, a Sanofi Company | 2010-08-01 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants (NCT01090453) | GlaxoSmithKline | 2010-05-17 |
| Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan (NCT01229579) | Aga Khan University | 2010-05-01 |
| Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine (NCT01105559) | Sanofi | 2010-04-01 |